Article

Patients can upgrade to medication with Purite twice daily

Since its introduction in 1996, brimonidine 0.2% (Alphagan, Allergan) has fast become a core member in the physician's arsenal of effective first-line IOP-lowering agents. Few find this surprising, given the drug's strong history in clinical trials proving its efficacy as a monotherapy,1 adjunctive, or replacement therapy.2,3 But as my fellow prescribers know, when opting for brimonidine 0.2%, some level of consideration is given to the possible occurrence of allergic conjunctivitis, which has been previously reported in 12.7% of patients.4

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI Myopia Workshop: Michael X. Repka, MD, MBA, on building consensus and future directions
(Image credit: Ophthalmology Times) Introducing iOpeners: Unpacking high-yield ophthalmology tips and clinical pearls, with Nicole Bajic, MD
© 2025 MJH Life Sciences

All rights reserved.